DIRS.INFO The most relevant business & tech news

☆ ‘Lift’ Review: Thin as Thieves
▼ + stars: | 2024-01-11 | by ( Robert Daniels | ) www.nytimes.com time to read: +1 min

Kevin Hart plays Cyrus, a master thief, in the undercooked heist flick, “Lift,” directed by F. Gary Gray. Beyond the windfall Jorgensen will get from shorting water utility stocks, it’s unclear what he gains from this elaborate ruse. An Interpol agent, Abby (Gugu Mbatha-Raw), enlists Cyrus to steal the passenger plane carrying the gold bars before any damage can be done. Although Abby and Cyrus are old flames, the film doesn’t pick up any romantic steam, either, thanks to what passes for banter. “I was looking at the questions that weren’t being asked,” Cyrus tells Abby.

Persons: Kevin Hart, Cyrus, ”, Gary Gray, Daniel Kunka, Lars Jorgensen, Jean Reno, Jorgensen, Abby, Gugu, “, weren’t, ” Cyrus Organizations: Interpol Locations: Tuscany, Venice

The assessment could become politically divisive as it sets the stage for the next few years of global action in cutting planet-warming emissions. Based on the results, countries may be pressed to set more ambitious climate policies or to contribute more financing to help developing countries adopt clean energy. In September, the United Nations offered an early stocktake assessment that revealed countries were far behind in meeting climate goals. HOW WILL THE STOCKTAKE DRIVE CLIMATE ACTION? What then needs to be decided... what do we then do from here," Dan Jorgensen, Denmark's Global Climate Policy Minister, told Reuters.

Persons: Alex Flores, Claudia Morales, Dan Jorgensen, Kate Abnett, Katy Daigle, Josie Kao Organizations: REUTERS, Rights, United Nations, European Union, Policy, Reuters, Thomson Locations: Lake Titicaca, Bolivia, Rights DUBAI, Dubai, Paris

Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsSummaryCompanies Novo racing to meet demand for obesity drugsObesity market to reach $100 billion by 2030-analystsNew investment in France will boost capacity for obesity, diabetes drugsPARIS/LONDON Nov 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Thursday announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France as it races to meet soaring demand. There is a growing crisis in Europe over supply of diabetes therapy Ozempic, which uses the same ingredient semaglutide as the hugely popular weight-loss drug Wegovy, which is not yet widely available in Europe. Thursday's announcement comes after Novo earlier this month announced a $6 billion investment in its native Denmark to boost production. Analysts have estimated the obesity drug market will be worth as much as $100 billion by 2030.

Persons: Victoria Klesty, Danish drugmaker, Emmanuel Macron, Lars Fruergaard Jorgensen, Eli Lilly, Novo, Anna Ringstrom, Ludwig Burger, Terje Solsvik, David Goodman, Emelia Organizations: REUTERS, Novo Nordisk, WIN, French, Thomson Locations: Oslo, Norway, Victoria, France, PARIS, Chartres, Danish, Europe, Union, Germany, Belgium, Denmark, U.S, Paris

The company's research and development (R&D) engine is intact and therefore it is unlikely to do transformative deals soon, Jorgensen said. It was the latest in a series of similarly-sized deals the company has done this year. Last week, when reporting quarterly earnings, it forecast another year of double-digit sales growth for its two most popular drugs: weight-loss drug Wegovy and diabetes Ozempic. To keep up with demand, Novo is racing to increase production of those drugs, which contain the same active pharmaceutical ingredient, semaglutide, and are delivered in self-injection pens. A healthcare banker, speaking on condition of anonymity, told Reuters after the interview there were many companies in the cardiometabolic space with early-stage drugs that Novo Nordisk may be able to buy.

Persons: Lars Fruergaard Jorgensen, Wegovy, Jorgensen, Novo, Novo's, Jacob Gronholt, Maggie Fick, Terje Solsvik, Emelia, Barbara Lewis Organizations: Novo, Novo Nordisk, Reuters, KBP Biosciences, Nordisk, Pedersen, Thomson Locations: Novo, COPENHAGEN, Singapore, Copenhagen, London

As the company's fortunes soar on demand for its popular weight-loss medicine Wegovy, Jorgensen said Novo sought to acquire companies working on medicines in the areas where it is already focused. The company's research and development (R&D) engine is intact and therefore it is unlikely to do transformative deals soon, Jorgensen said. It was the latest in a series of similarly-sized deals the company has done this year. Last week, when reporting quarterly earnings, it forecast another year of double-digit sales growth for its two most popular drugs: weight-loss drug Wegovy and diabetes Ozempic. To keep up with demand, Novo is racing to increase production of those drugs, which contain the same active pharmaceutical ingredient, semaglutide, and are delivered in self-injection pens.

☆ ‘Orlando, My Political Biography’ Review: A Collective Approach to Joy
▼ + stars: | 2023-11-09 | by ( Manohla Dargis | More About Manohla Dargis | ) www.nytimes.com time to read: +3 min

Along the way, Preciado draws attention to the construction of identity and that of the movie itself, fusing form and subject. Preciado’s most provocative conceit is that he shares the role of Orlando with 20 other trans and nonbinary individuals of different ages, hues and shapes. Like her Orlando, his travels widely (if on a shoestring budget), undergoes metamorphoses and weaves through the centuries. By sharing the role of Orlando, Preciado shifts the story from the individual to the collective, taking it out of the private realm and into the public sphere. “I wouldn’t exactly say that either,” Orlando says with a Mona Lisa smile.

Persons: Woolf, ”, Christine Jorgensen, Orlando, Amir Baylly, Liz Christin, Dr, “, she’s, ” Orlando, Mona Lisa Organizations: Orlando Locations: Orlando

The House passed a GOP-led resolution on Tuesday to censure Rep. Rashida Tlaib over comments critical of Israel and in support of Palestinians amid Israel’s war against Hamas. The vote was 234 to 188 with four Republicans voting against and 22 Democrats voting in support of the censure resolution. Both censure resolutions reference the chant. But those reports were contradicted by American intelligence, which subsequently concluded that the Israel Defense Forces were not responsible for the explosion. Greene’s resolution accuses Tlaib of “lying about Israel’s responsibility for the attack.”In a statement on the two censure resolutions, Tlaib said, “It’s a shame my colleagues are more focused on silencing me than they are on saving lives, as the death toll in Gaza surpasses 10,000.

Persons: Rashida, Rich McCormick, Tlaib, it’s, “, ”, Ilhan Omar, Minnesota, Marjorie Taylor Greene, Greene, ” Tlaib, Hakeem Jeffries, “ Joe Biden, Biden, McCormick, It’s, Julie Singleton, McCormick’s, Tlaib “, Israel, ” “, ” CNN’s Manu Raju, Sam Fossum Organizations: GOP, Hamas, Michigan Democrat, Georgia GOP, Democratic, GOP Rep, Capitol, Defamation League, CNN, Capitol Police, Israel Defense Forces, “ Media, Gaza Ministry of Health, United Nations, United, American Locations: Israel, Palestinian, Tlaib, Palestine, ”, Cumming , Georgia, Gaza, United States

☆ EU proposal may accelerate pharma innovation decline, industry group says
▼ + stars: | 2023-11-06 | by ( Julia Payne | ) www.reuters.com time to read: +3 min

"Any changes to our incentives system would equally affect EU-based and foreign-based companies which bring medicines to the EU and, therefore, it would not put EU firms at a disadvantage," an EU Commission spokesperson said. Medication was the single biggest contributor to the EU’s trade surplus, with 235 billion euro ($252.13 billion) worth of exports in 2021. The EFPIA said small biotech companies have already moved to the United States and China. The Commission said its proposal would reduce new medicine approval times to 180 days from 400 days. Germany, Belgium and France would be the hardest hit by the proposed rules, the EFPIA said citing research by Dolon that it commissioned.

Persons: EFPIA, Lars Fruergaard Jorgensen, Jorgensen, Ozempic, " Jorgensen, Julia Payne, Lisa Shumaker Organizations: European Commission, European Federation of Pharmaceutical Industries, EU, Commission, Novo Nordisk, Thomson Locations: BRUSSELS, United States, China, Danish, Boston, U.S, Europe, EU, Germany, Belgium, France

☆ Novo Nordisk owner invests $290 million in energy transition fund
▼ + stars: | 2023-09-14 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

FILE PHOTO-A coffee machine featuring Novo Nordisk logo is seen at the company headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowLONDON, Sept 14 (Reuters) - The controlling shareholder in drugmaker Novo Nordisk on Thursday announced a major investment in a new energy transition fund as it expands its portfolio beyond health. Novo Holdings controls 76% of the votes in Denmark's Novo Nordisk (NOVOb.CO), which became Europe's most valuable company last week on the back of soaring profits from its weight-loss drug Wegovy and type 2 diabetes drug Ozempic. Novo Holdings' capital to invest is burgeoning on Novo Nordisk's financial performance. Novo Holdings is wholly owned by the Novo Nordisk Foundation, which lists its aims as providing "a stable basis for the commercial and research activities conducted by the companies within the Novo Group", of which Novo Nordisk is the largest, and supporting "scientific, humanitarian, and social purposes."

Persons: Jacob Gronholt, Pedersen, Morten Beck Jorgensen, " Jorgensen, Maggie Fick, Amanda Cooper, Elaine Hardcastle Organizations: Novo Nordisk, REUTERS, drugmaker Novo Nordisk, Novo Holdings, Denmark's, Denmark's Novo Nordisk, Holdings, Glentra Capital, Glentra, Reuters, Novo, Novo Nordisk Foundation, Thomson Locations: Copenhagen, Denmark, drugmaker Novo, Denmark's Novo, Glentra Capital

☆ Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly
▼ + stars: | 2023-09-10 | by ( Maggie Fick | ) www.reuters.com time to read: +5 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. Studies have demonstrated more weight loss than with Wegovy. Novo's type 2 diabetes drug Ozempic has been on the market in Britain since 2019. A Lilly spokesperson declined to comment on Wegovy's launch or when exactly it would launch Mounjaro for diabetes treatment. Studies have shown that, used alongside exercise and lifestyle changes, Wegovy led to 15% weight loss over 68 weeks, while Mounjaro led to more than 22% over 72 weeks.

Persons: Victoria Klesty, Eli Lilly's, Wegovy, Lars Fruergaard Jorgensen, Novo, Lilly, Mounjaro, Ozempic, Eli Lilly, Maggie Fick, Alexander Smith, Catherine Evans Organizations: REUTERS, Wegovy, Economic Co, Development, Reuters, National Health Service, stoke, NHS, Britain's Department of Health, Social Care, Diabetes, UBS, Novo, Thomson Locations: Oslo, Norway, August31, Victoria, Britain, British, Danish, United States, Denmark, Germany, Europe, England

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ The obesity drug boom is just getting started: podcast
▼ + stars: | 2023-09-05 | by ( Aimee Donnellan | ) www.reuters.com time to read: +1 min

A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsLONDON, Sept 5 (Reuters Breakingviews) - Over 1 bln people are obese, the WHO reckons. Denmark’s Novo Nordisk is ahead of the pharma pack with its Wegovy weight-loss drug. Listen to the podcastFollow @aimeedonnellan on XSubscribe to Breakingviews’ podcasts, Viewsroom and The Exchange. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Victoria Klesty, Lars Jorgensen, Oliver Taslic Organizations: REUTERS, Reuters, WHO, Denmark’s, Denmark’s Novo Nordisk, pharma, Thomson Locations: Oslo, Norway, Victoria, Denmark’s Novo

☆ Novo says Wegovy drug helps obese people with heart failure in trial
▼ + stars: | 2023-08-25 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

FILE PHOTO: A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. The trial with 529 volunteers focused on a heart condition known as preserved ejection fraction, or HFpEF, where heart muscles stiffen and draw in less blood, mainly affecting overweight people. HFpEF accounts for about half of heart failure cases, with symptoms including shortness of breath and swelling of extremities. Showing specific medical benefits is crucial for Novo's push to move Wegovy beyond its image as a lifestyle drug. It is unclear, though, what conclusions regulators and physicians will draw from the STEP HFpEF results because other heart failure treatments are emerging.

Persons: Jim Vondruska, Wegovy, ”, Martin Lange, Danish drugmaker, Farxiga, Lars Fruergaard Jorgensen, Ludwig Burger, Jason Neely, Mark Potter Organizations: REUTERS, Novo Nordisk, Novartis, Reuters, Thomson Locations: Chicago , Illinois, U.S, Danish, Novo, United States, Europe, Germany

☆ Novo Nordisk CEO 'confident' Catalent will resolve Wegovy output problems
▼ + stars: | 2023-08-25 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

[1/3] A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. REUTERS/Yves Herman/File Photo Acquire Licensing RightsAug 25 (Reuters) - Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said on Friday he was confident Catalent (CTLT.N) would resolves its problems making Novo's hugely-popular weight-loss drug Wegovy as the company scrambles to boost output to meet soaring demand. "I am confident in that," Jorgensen said at a Reuters Newsmaker event, when asked about the issues Catalent has had. Novo hopes to have a third external facility filling and finishing the injection pens by 2024, Jorgensen said. Even so, it will be "quite some years" before the company can satisfy the whole market for Wegovy, Jorgensen said.

Persons: Yves Herman, Lars Fruergaard Jorgensen, Jorgensen, Catalent, Novo, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Novo Nordisk, Reuters, Wegovy, Thomson Locations: Brussels, Belgium, Danish

Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. The self-injection drug has transformed the fortunes of Novo, whose shares have surged about 165% since Wegovy's U.S. launch two years ago. The lion's share may be claimed by frontrunners Novo and its U.S. rival Eli Lilly and Co (LLY.N). Last month, Novo launched Wegovy in Germany, its first big European market. Reporting by Maggie Fick and Jacob Gronholt-Pedersen Editing by Josephine Mason and Mark PotterOur Standards: The Thomson Reuters Trust Principles.

Persons: Novo Nordisk Lars Fruergaard Jorgensen, LUDOVIC MARIN, Lars Fruergaard Jorgensen's, Jorgensen, Eli Lilly, Wegovy, Novo, Maggie Fick, Jacob Gronholt, Pedersen, Josephine Mason, Mark Potter Organizations: Novo Nordisk, Chateau, BMI, Reuters, frontrunners Novo, Pfizer, Thomson Locations: Versailles, Paris, COPENHAGEN, Europe, Danish, United States, Denmark, Norway, Brussels, Wegovy, Germany

Companies Novo Nordisk A/S FollowCOPENHAGEN, Aug 10 (Reuters) - Novo Nordisk's (NOVOb.CO) limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will last into next year even as the Danish drugmaker spends billions boosting output, its CEO told Reuters on Thursday. Earlier on Thursday, the company said it would continue to restrict U.S. supplies of starter doses of Wegovy as the company struggles to keep up with soaring demand. Novo has denied this, but when asked about this on Thursday Jorgensen said there may be shortages. The company expects to apply for regulatory approval for an expanded label indication in the U.S. and European Union later this year. "It'll take some time before we get it on label," Jorgensen said.

Persons: Lars Fruergaard Jorgensen, Thursday Jorgensen, Jim Vondruska, Jorgensen, " Jorgensen, Martin Lange, Nikolaj Skydsgaard, Jacob Gronholt, Josephine Mason, Jason Neely, Mark Potter Organizations: Novo Nordisk, COPENHAGEN, Reuters, REUTERS, Wegovy, Union, American Heart Association, Pedersen, Thomson Locations: Danish, Chicago , Illinois, U.S, Philadelphia, Copenhagen, London

☆ Novo Nordisk extends U.S. supply curbs on weight-loss drug Wegovy
▼ + stars: | 2023-08-10 | by ( Nikolaj Skydsgaard | ) www.reuters.com time to read: +3 min

The news came as the Danish drugmaker raised its full-year profit and sales forecasts for a second time. Wegovy is a weekly injection that can help patients to shed 15% of their weight alongside diet and exercise changes. Reuters has reported that larger doses are also in short supply, which Novo has denied. Many analysts had expected Novo to raise earnings guidance, given the huge U.S. demand for the weekly injection. The company also warned that it expected "continued periodic" supply constraints and drug shortages across a number of products and geographies.

Persons: Jacob Gronholt, Pedersen, Ozempic, Lars Fruergaard Jorgensen, Novo, " Jorgensen, Henrik Hallengreen Laustsen, Laustsen, Nikolaj Skydsgaard, Josephine Mason, Mark Potter Organizations: Novo Nordisk, REUTERS, Reuters, World Health Organization, Jyske Bank, Thomson Locations: Novo, Copenhagen, Denmark, U.S, COPENHAGEN, Danish

☆ Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
▼ + stars: | 2023-08-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company's blockbuster weight loss portfolio. The deal's price depends on whether Inversago reaches certain development and sales goals, Novo Nordisk said in a release. Canada-based Inversago develops experimental therapies to treat people with obesity, diabetes and other conditions affecting the body's metabolism. Meanwhile, Novo Nordisk's Wegovy and Ozempic work by mimicking a hormone produced in the gut to suppress a person's appetite. Novo Nordisk intends to further investigate the potential of the oral drug for obesity and obesity-related complications.

Persons: Novo, Martin Holst Lange, Lars Fruergaard Jorgensen, availabilities Organizations: Novo Nordisk, Inversago Pharma, Novo, Novo Nordisk's Wegovy, Nordisk, Reuters Locations: Danish, Inversago, Canada, U.S

[1/3] A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. It highlights the challenge Novo and rivals face in convincing European governments to pay for obesity drugs, which analysts say is likely to slow their take-up there. Germany's health ministry told Reuters there were no plans to change the law to cover weight loss drugs. DIFFERENT PICTUREIn the United States, the federal Medicare health plan for older Americans is prohibited from covering weight-loss drugs. Many health plans paid for by large employers will cover Wegovy, although they may require that patients try a rigorous diet programme or cheaper drugs first.

Persons: Jim Vondruska, Wegovy, Martin Merkel, Merkel, Duane Mellor, Novo, Lars Fruergaard Jorgensen, Michael Wirtz, Terence McManus, Phil McEwan, they've, McEwan, Patricia Weiss, Josephine Mason, Catherine Evans Organizations: REUTERS, Novo Nordisk, Wegovy, Europe's, pharma, European Union, Endocrinology Society, Aston University in, Reuters, Bellevue Asset Management, Barclays, Thomson Locations: Chicago , Illinois, U.S, Germany, FRANKFURT, Aston University in Birmingham, England, Wegovy, Europe, Danish, Berlin, Norway, Denmark, Britain, United States, Switzerland, Bellevue, EU, Cardiff , Wales, Frankfurt

☆ An earthquake destroyed their California home days before Christmas. They still have to pay the mortgage
▼ + stars: | 2023-07-02 | by ( Nouran Salahieh | ) edition.cnn.com time to read: +14 min

A 6.4 magnitude earthquake had just struck Rio Dell, California, upending homes and lives for the community of 3,400 people near Oregon. “It’s a gamble to not have it,” Rio Dell City Manager Kyle Knopp said. A whopping 90% of homes in California aren’t covered by earthquake insurance, according to Glenn Pomeroy, CEO of the California Earthquake Authority, a nonprofit quake insurer established by the state. Gavin Newsom proclaimed an emergency for Humboldt County, where Rio Dell is located, in part to help local governments access services. Despite seeing how costly earthquake damage can be, she doubts she’ll buy earthquake insurance for her next home.

Persons: CNN —, Jacqui McIntosh, Rio, McIntosh, ”, unlivable, “ It’s, Fred Greaves, “, Kyle Knopp, Glenn Pomeroy, ” Brian Ferguson, Knopp, ” Knopp, Randy Jensen, ” Jensen, Jensen, Jane Tyska, ” Pomeroy, that’s, Pomeroy, Gavin Newsom, Michelle Bushnell, Bushnell, it’s, Keith Porter, Kent Porter, Bolt, Porter, ” Porter, ‘, Alyssa Jorgensen, Jorgensen, didn’t, ” McIntosh Organizations: CNN, Dell, California Earthquake Authority, California Governor’s, Emergency Services, Mendocino Triple Junction, FEMA, Rio Dell, Reuters, Rio Dell Water, Media, East Bay Times, San, Small Business Administration, Institute, The Press Democrat, Mitigation, retrofits, Earthquake, California Earthquake Locations: Rio Dell , California, Oregon, Rio Dell, California, It’s, Mendocino, Cape Mendocino, Northern California, Montecito, Beverly Hills, Malibu, Rio, Humboldt County

☆ Fed, ECB may slash bank reserves by 90% in new era of high rates - paper
▼ + stars: | 2023-06-22 | by ( ) www.reuters.com time to read: +3 min

FRANKFURT, June 22 (Reuters) - The Federal Reserve and the European Central Bank may mop up as much as 90% of the money they pumped into banks over the last decade now that high inflation and interest rates make that extra liquidity unnecessary, a paper by a Fed economist showed on Thursday. The world's two largest central banks have been raising interest rates at a brisk pace to fight inflation and unwinding some of their massive bond purchases, which flooded banks with cash when price growth was sluggish and borrowing costs already at zero. Neither scenario is entirely plausible in the near term as both the Fed and the ECB have a mix of government bonds and other types of debt on their balance sheet. The paper narrowly focuses on the supply and demand of reserves and the relative convenience of assets received by the central banks in return. ($1 = 0.9093 euros)Reporting by Francesco Canepa Editing by Christina FincherOur Standards: The Thomson Reuters Trust Principles.

Persons: Annette Vissing, Jorgensen, Francesco Canepa, Christina Fincher Organizations: Federal Reserve, European Central Bank, ECB, Federal Reserve Board, Fed, Thomson Locations: FRANKFURT, Portugal

A weekly injection of Wegovy leads to an average weight loss of around 15%, alongside changes to diet and exercise. That has effectively delayed the launch in most of Europe, following the recent launch of Wegovy in Denmark and Norway. Novo Nordisk has also had to overcome problems at a contract manufacturer. Novo Nordisk also said the number of people with obesity is forecast to rise to 1.5 billion by 2035. Research and development chief Martin Lange said that the company plans to investigate how to maintain the weight loss after stopping the drug.

Persons: Lars Fruergaard Jorgensen, Camilla Sylvest, Jorgensen, Wegovy, Martin Lange, Maggie Fick, Nikolaj Skydsgaard, Jennifer Rigby, Louise Heavens, Emma Rumney Organizations: pharma, Novo Nordisk, World Health Organisation, WHO, World Obesity Federation, Reuters, Research, Thomson Locations: COPENHAGEN, Europe, United States, U.S, Danish, Wegovy, Denmark, Norway, London, Copenhagen

☆ Italians judge Spanish pizzeria as the best in Europe
▼ + stars: | 2023-05-04 | by ( Julia Buckley | ) edition.cnn.com time to read: +6 min

Enter 50 Top Pizza, an international guide run by Italians that produces a series of annual rankings rewarding some of the best pizzerias on the planet. The 2023 European list has just been published – and, according to 1,000 anonymous “inspectors” across the continent, the best pizza in Europe is in… Spain. The entity – a pizza guide, which has been ranking restaurants since 2017 – has separate listings for the 50 best pizzerias in the cradle of pizza. The best pizza was judged to be Panatieri's "Salsa de tomates cherry asados, mozzarella y holandesa de albahaca." Today this is not the case.”As for the Italy rankings, they will be revealed in Rome on July 12.

☆ Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demand
▼ + stars: | 2023-05-04 | by ( Nikolaj Skydsgaard | ) www.reuters.com time to read: +3 min

SummarySummary Companies Novo halves supply of Wegovy starter doses in U.S. "To safeguard continuity of care, the supply of the lower Wegovy dose strengths in the US will be reduced temporarily," Novo said in a statement. Novo has faced supply constraints for its hugely popular Wegovy drug as a result of overwhelming demand, and has invested massively in increasing supply. Supply of starter doses in the U.S. would be cut by around 50% for "some months," Jorgensen added. Credit Suisse analysts said they were not surprised by the move, given the level of demand for the drug.

☆ Novo Nordisk’s chunky valuation risks crash diet
▼ + stars: | 2023-05-04 | by ( Aimee Donnellan | ) www.reuters.com time to read: +4 min

LONDON, May 4 (Reuters Breakingviews) - Novo Nordisk’s (NOVOb.CO) weighty valuation could be headed for a crash diet. This lofty position is thanks to its domination of the obesity market via its Wegovy drug. Obesity sales for Novo are still only expected to reach $12 billion by 2027, according to estimates from Visible Alpha. It also remains unclear how fast the obesity drug market will grow. Novo reported earnings before interest and taxes of 25 billion Danish crowns ($3.72 billion), above an average analyst forecast of 22.4 billion, according to a Refinitiv poll.

Search resuls for: "" Jorgensen"

25 mentions found